Last reviewed · How we verify
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg is a Biologic drug developed by The University of Queensland. It is currently in Phase 1 development.
At a glance
| Generic name | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg |
|---|---|
| Sponsor | The University of Queensland |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg CI brief — competitive landscape report
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg updates RSS · CI watch RSS
- The University of Queensland portfolio CI
Frequently asked questions about MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
What is MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg?
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg is a Biologic drug developed by The University of Queensland.
Who makes MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg?
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg is developed by The University of Queensland (see full The University of Queensland pipeline at /company/the-university-of-queensland).
What development phase is MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg in?
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg is in Phase 1.